{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:34Z","timestamp":1789609114062,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejca.2024.115049","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T21:33:29Z","timestamp":1727472809000},"page":"115049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study"],"prefix":"10.1016","volume":"212","author":[{"given":"C.","family":"Ertl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Piseddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Garza Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kabakci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bonczkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.N.","family":"de Toni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"David-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Srour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tomsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2024.115049_bib1","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jtho.2021.06.024","article-title":"Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events","volume":"16","author":"Luo","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.115049_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092538","article-title":"Steroid-refractory immune-related adverse events induced by checkpoint inhibitors","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ejca.2024.115049_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2024.115049_bib4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2024.115049_bib5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.115049_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"36","key":"10.1016\/j.ejca.2024.115049_bib7","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115049_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115049_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113505","article-title":"The side effect registry immuno-oncology (SERIO) \u2013 a tool for systematic analysis of immunotherapy-induced side effects","volume":"199","author":"Ertl","year":"2024","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2024.115049_bib10","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2024.115049_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.115049_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/ajco.13332","article-title":"The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events","volume":"16","author":"Wang","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.115049_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3892\/mco.2021.2227","article-title":"Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: a retrospective study","volume":"14","author":"Kadokawa","year":"2021","journal-title":"Mol Clin Oncol"},{"issue":"1-2","key":"10.1016\/j.ejca.2024.115049_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2012.04.016","article-title":"Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil","volume":"249","author":"Termsarasab","year":"2012","journal-title":"J Neuroimmunol"},{"issue":"12","key":"10.1016\/j.ejca.2024.115049_bib15","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced melanoma","volume":"8","author":"Van Not","year":"2022","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.115049_bib16","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2024.115049_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1039\/c2pp25144b","article-title":"Photopheresis (extracorporeal photochemotherapy)","volume":"12","author":"Trautinger","year":"2013","journal-title":"Photochem Photobiol Sci"},{"issue":"2","key":"10.1016\/j.ejca.2024.115049_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjh.14537","article-title":"The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society","volume":"177","author":"Alfred","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ejca.2024.115049_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00105-018-4327-y","article-title":"Single-center retrospective analysis of extracorporal photopheresis in clinical practice: peripheral venous compared to central venous access","volume":"70","author":"Hambsch","year":"2019","journal-title":"Hautarzt"},{"issue":"10","key":"10.1016\/j.ejca.2024.115049_bib20","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/trf.12059","volume":"53","author":"Pierelli","year":"2013","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.ejca.2024.115049_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ncponc0511","article-title":"Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression?","volume":"3","author":"Marshall","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2024.115049_bib22","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1111\/jdv.16890","article-title":"European dermatology forum \u2013 updated guidelines on the use of extracorporeal photopheresis 2020 \u2013 Part 1","volume":"34","author":"Knobler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.ejca.2024.115049_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jdv.16889","article-title":"European dermatology forum: updated guidelines on the use of extracorporeal photopheresis 2020 \u2013 Part 2","volume":"35","author":"Knobler","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2024.115049_bib24","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fmed.2018.00236","article-title":"Extracorporeal photopheresis\u2013an overview","volume":"5","author":"Cho","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.ejca.2024.115049_bib25","doi-asserted-by":"crossref","first-page":"1086006","DOI":"10.3389\/fimmu.2023.1086006","article-title":"Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers","volume":"14","author":"Bojanic","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2024.115049_bib26","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3389\/fimmu.2018.02207","article-title":"Modulation of B cells and homing marker on NK cells through extracorporeal photopheresis in patients with steroid-refractory\/resistant graft-vs.-host disease without hampering anti-viral\/anti-leukemic effects","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2024.115049_bib27","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8118.1","article-title":"Extracoporeal photopheresis treatment of acute graft-versus-host disease following allogeneic haematopoietic stem cell transplantation","volume":"5","author":"Flinn","year":"2016","journal-title":"F1000Res"},{"issue":"10","key":"10.1016\/j.ejca.2024.115049_bib28","first-page":"2004","article-title":"Extracorporeal photopheresis and cyclophosphamide for cancer-associated systemic sclerosis worsening induced by immune checkpoint inhibitors: a case report","volume":"40","author":"Gaillet","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ejca.2024.115049_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMc1912274","article-title":"Extracorporeal photopheresis for colitis induced by checkpoint-inhibitor therapy","volume":"382","author":"Apostolova","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2024.115049_bib30","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.115049_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CJI.0000000000000510","article-title":"Extracorporeal photopheresis as a treatment option for immune-related adverse events: Two case reports and a prospective study","volume":"47","author":"Ruf","year":"2024","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2024.115049_bib32","doi-asserted-by":"crossref","first-page":"1408586","DOI":"10.3389\/fcvm.2024.1408586","article-title":"Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity","volume":"11","author":"Wang","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.ejca.2024.115049_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2024.115049_bib34","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1111\/ajco.12651","article-title":"Infliximab for ipilimumab-induced colitis: a series of 13 patients","volume":"13","author":"Hillock","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2024.115049_bib35","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115049_bib36","article-title":"Checkpoint Inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological and gene expression level","author":"Zecha","year":"2024","journal-title":"JAAD Int"},{"key":"10.1016\/j.ejca.2024.115049_bib37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients' health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2024.115049_bib38","article-title":"Effects of extracorporeal photopheresis on quality of life and the course of diseases in patients with mycosis fungoides and graft-versus-host disease: a single-center analysis","volume":"15","author":"Vogiatzis","year":"2023","journal-title":"Cureus"},{"issue":"5 Pt 1","key":"10.1016\/j.ejca.2024.115049_bib39","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0190-9622(99)70167-2","article-title":"Quality of life improvement in a patient with severe atopic dermatitis treated with photopheresis","volume":"40","author":"Mohla","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2024.115049_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa'ak","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.115049_bib41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.115049_bib42","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jtcvs.2015.07.056","article-title":"Instrumental variable methods in clinical research","volume":"150","author":"Bagiella","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"12","key":"10.1016\/j.ejca.2024.115049_bib43","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1007\/s00262-022-03211-7","article-title":"Checkpoint-inhibitor induced polyserositis with edema","volume":"71","author":"Zierold","year":"2022","journal-title":"Cancer Immunol Immunother"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924010153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924010153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T21:30:44Z","timestamp":1737667844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924010153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":43,"alternative-id":["S0959804924010153"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115049","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115049"}}